BAMF Health has received another significant donation to its Foundation for Medical Advancement and Breakthroughs, or FMAB. Dr. Abass Alavi, a pioneering figure in the field of molecular imaging and nuclear medicine, and his wife Jane Alavi, made a $100,000 donation toward continued research through FMAB.
“BAMF Health has built a unique infrastructure that integrates cutting-edge molecular imaging, Theranostics, and AI-driven analytics under one roof,” said Dr. Alavi. “Few institutions worldwide have the capability to advance nuclear medicine in such a comprehensive way. My decision to support BAMF stems from the recognition that our collaboration has the potential to bring transformative changes to research and patient care.”
A Rare and Significant Gesture
BAMF Health Chief Medical Advisor, Dr. Harshad Kulkarni said, “Dr. Alavi’s donation to BAMF Health is a deeply meaningful gesture that underscores his belief in the transformative potential of Theranostics and molecular imaging. As one of the foremost leaders in the field, his decision to support BAMF is a strong testament to the impact of our work and our vision for the future.”
Philanthropic contributions from individuals of Dr. Alavi’s stature are rare. His support represents not only financial backing but also a recognition of BAMF’s role in pioneering new frontiers in precision medicine. It also fosters a closer collaboration that will accelerate innovation, research, and real-world clinical applications that directly benefit patients.
“The primary goal of this contribution is to fuel research initiatives that push the boundaries of Theranostics and molecular imaging,” Dr. Alavi shared. “I hope it will enable BAMF to pursue ambitious projects that lead to the development of new imaging and therapeutic strategies. By advancing PET imaging methodologies, refining treatment response assessments, and exploring new applications for nuclear medicine, we can significantly improve how diseases are diagnosed and treated.”
Current and Future Research Between Dr. Alavi and BAMF Health
Dr. Alavi and researchers at BAMF Health have been collaborating for years. Our joint efforts have explored a number of approaches including innovative applications of total-body PET imaging in oncology and hematologic conditions, with a broader vision to push the frontiers of precision medicine.
Dr. Alavi’s last visit to BAMF was in 2023. The visit focused on aligning research priorities, reviewing existing datasets for retrospective studies, and laying the groundwork for prospective studies, particularly in areas such as PET-based imaging of atherosclerosis, oncology, and neurodegenerative diseases.
Moving forward, our goal is to expand these initiatives, leveraging BAMF’s infrastructure to conduct large-scale, high-impact studies that address unmet clinical needs. We also aim to optimize methodologies for total-body PET imaging, advance AI-driven analytics in nuclear medicine, and refine Theranostics treatment monitoring protocols.
Dr. Kulkarni added, “For BAMF, this contribution will enhance our ability to conduct high-impact studies, acquire and analyze complex imaging datasets, and translate research into clinical practice. For the broader scientific community and patients, it will mean faster progress in developing advanced imaging techniques, refining treatment strategies, and ultimately improving patient outcomes.”
Supporting the Next Generation of Innovation
“This donation is not just about financial support—it represents a commitment to accelerating innovation in nuclear medicine and ensuring that the next generation of imaging and Theranostics experts have the resources they need to continue advancing the field,” Dr. Alavi said. “I look forward to seeing the impact of this collaboration unfold in the coming years.”
Dr. Alavi has plans to visit BAMF Health again in early 2025.
About Dr. Abass Alavi
Dr. Abass Alavi is widely regarded as a luminary in nuclear medicine and molecular imaging. He played a pivotal role in the development and clinical adoption of PET imaging, fundamentally transforming how diseases are diagnosed and monitored. His research has spanned oncology, cardiology, neurology, and metabolic disorders, leading to paradigm shifts in medical imaging.
His pioneering work with FDG-PET imaging revolutionized the diagnosis and management of cancer and neurodegenerative diseases. Over the decades, he has contributed to groundbreaking advancements in imaging biomarkers, quantitative PET analysis, and novel applications of PET in emerging disease areas.
In Theranostics, his insights into molecular imaging have been instrumental in refining patient selection criteria, optimizing treatment monitoring, and developing new imaging agents. His continued contributions are shaping the future of precision medicine, making his partnership with BAMF a significant step forward in the evolution of the field.
